The presentation, scheduled for October 26, 2026, will center on the efficacy of the drug—internationally referred to as Bulumtatug Fuvedotin—in patients diagnosed with locally advanced or metastatic triple-negative breast cancer. Specifically, the data highlights outcomes for participants who have previously undergone treatment with topoisomerase I inhibitor-based ADCs, a critical patient cohort in the current oncology landscape. Professor ZHANG Jian from the Fudan University Shanghai Cancer Center will lead the oral presentation, designated as abstract 4640RO, during the advanced breast cancer session. This study marks a significant milestone for the Shanghai-based company as it continues to advance its oncology pipeline through global clinical forums.
Mabwell to Unveil Phase 2 Data on Nectin-4 ADC at ESMO 2026
Clinical researchers will shift their focus to the potential of the Nectin-4-targeting antibody-drug conjugate 9MW2821 this October, as Shanghai-based biopharmaceutical firm Mabwell prepares to present new results from a Phase 2 study at the 2026 European Society for Medical Oncology Annual Congress in Madrid.
Comments (0)
No comments yet. Be the first!